Mark A. Behlke, M.D., Ph.D.

Mark Behlke, M.D., Ph.D.As the Chief Scientific Officer, Dr. Behlke directs activities at IDT across a variety of new product development and basic research areas including functional genomics (RNAi and antisense), DNA thermodynamics, probe chemistries, amplification methods, and next generation sequencing technologies. He has directed research activities at IDT since joining the company in 1995. Dr. Behlke (together with Dr. John Rossi, from the Beckman Research Institute at the City of Hope) is a scientific co-founder of Dicerna Pharmaceuticals, located in Boston, Massachusetts and is a member of the Dicerna Scientific Advisory Board.

Before joining IDT, Dr. Behlke was a Physician Postdoctoral Fellow of the Howard Hughes Medical Institute at the Whitehead Institute for Biomedical Research, MIT, where he studied human sex determination in the laboratory of Dr. David Page. He was a Resident Physician in Internal Medicine and Fellow in Endocrinology at Brigham and Women’s Hospital, Boston. Dr. Behlke received his M.D. and Ph.D. degrees from Washington University, St. Louis in 1988, where he studied immunogenetics in the laboratory of Dr. Dennis Loh. He received his B.S. degree from the Massachusetts Institute of Technology in 1981.

Mark A. Behlke is an inventor on over 20 issued US patents, has numerous pending patent applications, and is author of over 90 scientific publications in peer-reviewed journals. He is an internationally recognized expert in nucleic acid technologies.